Short-term Efficacy and Safety of Intravitreal Brolucizumab Injection for Treatment-Naive Exudate Age-related Macular Degeneration: A Multicenter Study
2
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Purpose: To compare short-term efficacy and safety of intravitreal brolucizumab injection with aflibercept in treatment-naive neovascular age-related macular degeneration (nAMD) patients. Methods: A total of 59 eyes from 59 treatment-naive nAMD patients in three hospitals were retrospectively reviewed. Of which, 27 patients underwent intravitreal brolucizumab injections and 32 received aflibercept. After monthly consecutive three injections, best-corrected visual acuity (BCVA; in logarithm of minimal angle of resolution [logMAR]), central macular thickness (CMT), dry macula achievement rate, and intraocular inflammation (IOI) incidence were compared. Results: After loading-phase treatment, BCVA was significantly increased from 0.48 ± 0.30 logMAR at baseline to 0.33 ± 0.21 logMAR at 3 months in the brolucizumab group (p = 0.002) and 0.40 ± 0.39 logMAR at baseline to 0.33 ± 0.36 logMAR at 3 months in the aflibercept group (p = 0.007). But there was no significant difference in BCVA improvement at 3 months between the two groups. CMT significantly decreased from 429.67 ± 250.59 μm at baseline to 210.67 ± 93.53 μm at 3 months in the brolucizumab group and from 346.69 ± 159.09 μm to 234.52 ± 83.42 μm in the aflibercept group (both p < 0.001). The amount of CMT reduction was significantly greater in the brolucizumab group after 3 months (p = 0.036). In typical AMD eyes, brolucizumab showed similar BCVA improvement but better CMT reduction at 3 months (p = 0.018). Dry macula achievement rate was not significantly different between the two groups. One IOI was observed in the brolucizumab group. Conclusions: Intravitreal injections of brolucizumab and aflibercept showed similar anatomical and functional outcomes. But CMT reduction was greater in the brolucizumab group. One IOI was identified, which was tolerable for topical agents. These results suggest that brolucizumab could be a novel first line treatment option for treating naive nAMD patients.
Abstract
Purpose: To compare short-term efficacy and safety of intravitreal brolucizumab injection with aflibercept in treatment-naive neovascular age-related macular degeneration (nAMD) patients. Methods: A total of 59 eyes from 59 treatment-naive nAMD patients in three hospitals were retrospectively reviewed. Of which, 27 patients underwent intravitreal brolucizumab injections and 32 received aflibercept. After monthly consecutive three injections, best-corrected visual acuity (BCVA; in logarithm of minimal angle of resolution [logMAR]), central macular thickness (CMT), dry macula achievement rate, and intraocular inflammation (IOI) incidence were compared. Results: After loading-phase treatment, BCVA was significantly increased from 0.48 ± 0.30 logMAR at baseline to 0.33 ± 0.21 logMAR at 3 months in the brolucizumab group (p = 0.002) and 0.40 ± 0.39 logMAR at baseline to 0.33 ± 0.36 logMAR at 3 months in the aflibercept group (p = 0.007). But there was no significant difference in BCVA improvement at 3 months between the two groups. CMT significantly decreased from 429.67 ± 250.59 μm at baseline to 210.67 ± 93.53 μm at 3 months in the brolucizumab group and from 346.69 ± 159.09 μm to 234.52 ± 83.42 μm in the aflibercept group (both p < 0.001). The amount of CMT reduction was significantly greater in the brolucizumab group after 3 months (p = 0.036). In typical AMD eyes, brolucizumab showed similar BCVA improvement but better CMT reduction at 3 months (p = 0.018). Dry macula achievement rate was not significantly different between the two groups. One IOI was observed in the brolucizumab group. Conclusions: Intravitreal injections of brolucizumab and aflibercept showed similar anatomical and functional outcomes. But CMT reduction was greater in the brolucizumab group. One IOI was identified, which was tolerable for topical agents. These results suggest that brolucizumab could be a novel first line treatment option for treating naive nAMD patients.
참고문헌 (29)
- Pascolini D, "2002 Global update of available data on visual impairment : a compilation of population-based prevalence studies", Ophthalmic Epidemiol, 11, pp.67~115 (2004)
- Wong WL, "Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040 : a systematic review and meta-analysis", Lancet Glob Health, 2, pp.e106~16 (2014)
- Mitchell P, "Age-related macular degeneration", Lancet, 392, pp.1147~1159 (2018)
- Bakri SJ, "Safety and efficacy of anti-vascular endothelial growth factor therapies for neovascular age-related macular degeneration : a report by the American Academy of Ophthalmology", Ophthalmology, 126, pp.55~63 (2019)
- Ferris FL 3rd, "Clinical classification of age-related macular degeneration", Ophthalmology, 120, pp.844~851 (2013)
- Thomas CJ, "Age-related macular degeneration", Med Clin North Am, 105, pp.473~491 (2021)
- Holz FG, "Recent developments in the treatment of age-related macular degeneration", J Clin Invest, 124, pp.1430~1438 (2014)
- Sloan FA, "The effects of technological advances on outcomes for elderly persons with exudative age-related macular degeneration", JAMA Ophthalmol, 132, pp.456~463 (2014)
- Al-Zamil WM, "Recent developments in age-related macular degeneration : a review", Clin Interv Aging, 12, pp.1313~1330 (2017)
- van Asten F, "The cost-effectiveness of bevacizumab, ranibizumab and aflibercept for the treatment of age-related macular degeneration: a cost-effectiveness analysis from a societal perspective", PLoS One, 13, pp.e0197670~ (2018)
- Tadayoni R, "Brolucizumab : a newly developed anti-VEGF molecule for the treatment of neovascular age-related macular degeneration", Ophthalmologica, 244, pp.93~101 (2021)
- Sin M, "Brolucizumab : a new player in the field of anti-VEGF therapy of neovascular age-related macular degeneration : a review", Cesk Slov Oftalmol, 78, pp.3~8 (2022)
- Holz FG, "Single-chain antibody fragment VEGF inhibitor RTH258 for neovascular age-related macular degeneration : a randomized controlled study", Ophthalmology, 123, pp.1080~1089 (2016)
- Dugel PU, "HAWK and HARRIER:phase 3, multicenter, randomized, double-masked trials of brolucizumab for neovascular age-related macular degeneration", Ophthalmology, 127, pp.72~84 (2020)
- Dugel PU, "HAWK and HARRIER : ninety-six-week outcomes from the phase 3 trials of brolucizumab for neovascular age-related macular degeneration", Ophthalmology, 128, pp.89~99 (2021)
- Mones J, "Risk of inflammation, retinal vasculitis, and retinal occlusion-related events with brolucizumab: post hoc review of HAWK and HARRIER", Ophthalmology, 128, pp.1050~1059 (2021)
- Witkin AJ, "Brolucizumab-associated intraocular inf lammation in eyes without retinal vasculitis", J Vitreoretin Dis, 5, pp.326~332 (2021)
- Mishra SK, "Efficacy and safety of brolucizumab versus aflibercept in patients with neovascular age-related macular degeneration : a randomized trial in Indian patients", Int J Retina Vitreous, 8, pp.51~ (2022)
- Fukuda Y, "Comparison of outcomes between 3 monthly brolucizumab and aflibercept injections for polypoidal choroidal vasculopathy", Biomedicines, 9, pp.1164~ (2021)
- Ogura Y, "Efficacy and safety of brolucizumab versus aflibercept in eyes with polypoidal choroidal vasculopathy in Japanese participants of HAWK", Br J Ophthalmol, 106, pp.994~999 (2022)
- Ota H, "Switching from aflibercept to brolucizumab for the treatment of refractory neovascular age-related macular degeneration", Jpn J Ophthalmol, 66, pp.278~284 (2022)
- Hoshino J, "Intravitreal aflibercept versus brolucizumab for treatment-naive neovascular age-related macular degeneration with type 1 macular neovascularization : comparison of short-term outcomes", Ophthalmologica, 245, pp.413~420 (2022)
- Matsumoto H, "Short-term outcomes of intravitreal brolucizumab for treatment-naïve neovascular age-related macular degeneration with type 1choroidal neovascularization including polypoidal choroidal vasculopathy", Sci Rep, 11, pp.6759~ (2021)
- Baumal CR, "Expert opinion on management of intraocular inflammation, retinal vasculitis, and vascular occlusion after brolucizumab treatment", Ophthalmol Retina, 5, pp.519~527 (2021)
- Baumal CR, "Retinal vasculitis and intraocular inflammation after intravitreal injection of brolucizumab", Ophthalmology, 127, pp.1345~1359 (2020)
- Holz FG, "Intraocular inflammation with brolucizumab use : patient management-diagnosistherapy", Ophthalmologe, 118, pp.248~256 (2021)
- Kataoka K, "Three cases of brolucizumab-associated retinal vasculitis treated with systemic and local steroid therapy", Jpn J Ophthalmol, 65, pp.199~207 (2021)
- Witkin AJ, "Occlusive retinal vasculitis following intravitreal brolucizumab", J Vitreoretin Dis, 4, pp.269~279 (2020)
- Mukai R, "Risk factors for emerging intraocular inflammation after intravitreal brolucizumab injection for age-related macular degeneration", PLoS One, 16, pp.e0259879~ (2021)